Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes

Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life. Purpose and Methods This study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical immunology 2021-10, Vol.41 (7), p.1563-1573
Hauptverfasser: Bayram, Ozlem, Haskologlu, Sule, Bayrakoğlu, Deniz, Bal, Sevgi Kostel, Islamoglu, Candan, Cipe, Funda Erol, Kendirli, Tanil, Kursun, Nazmiye, Guner, Sukru Nail, Yildiran, Alisan, Bozdogan, Gunseli, Yuksek, Mutlu, Reisli, Ismail, Dalva, Klara, Aytekin, Caner, Boztug, Kaan, Dogu, Figen, Ikinciogullari, Aydan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1573
container_issue 7
container_start_page 1563
container_title Journal of clinical immunology
container_volume 41
creator Bayram, Ozlem
Haskologlu, Sule
Bayrakoğlu, Deniz
Bal, Sevgi Kostel
Islamoglu, Candan
Cipe, Funda Erol
Kendirli, Tanil
Kursun, Nazmiye
Guner, Sukru Nail
Yildiran, Alisan
Bozdogan, Gunseli
Yuksek, Mutlu
Reisli, Ismail
Dalva, Klara
Aytekin, Caner
Boztug, Kaan
Dogu, Figen
Ikinciogullari, Aydan
description Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life. Purpose and Methods This study reported retrospective data from 72 infants diagnosed with SCID including their major clinical features, HSCT characteristics, and outcomes over a 20-year period (1997–2017). Results Sixty-one of 72 SCID patients in the study underwent HSCT from 1997 to 2017. Median ages at the time of diagnosis and transplantation were 3.5 months and 5 months, respectively. Consanguinity was present in 68% of the patients, and T − B − NK + phenotype was predominantly identified. The overall survival was 80.3% over a 20-year period. However, the patients transplanted during an active infection had a lower survival rate of 73.9% compared to 100% for patients transplanted infection-free or with a previous infection that had resolved. The survival rate was significantly higher among recipients of HLA-identical transplants (92.9%), compared to recipients of mismatched related transplants (70%). The overall survival increased from 50 (1997–2006) to 85% (2007–2017) during the last 10 years. Conclusions This is one of the largest single-center studies in Turkey with extensive experience about SCID patients. Early diagnosis of SCID patients before the onset of an infection and early transplantation are shown to be extremely important factors affecting the outcome and increasing the survival regardless of the donor type based on the results of this study.
doi_str_mv 10.1007/s10875-021-01062-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2540518873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2574557817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d1620dc79b76ed16f0e6fd1188b36f6b2793470698ecfb5e59cb969399cfb3313</originalsourceid><addsrcrecordid>eNp9kU1rFTEUhoMo9rb6B1xIwI2baD4mycSdDLYWLlS4ug6ZzJmaMpPUZKZl_r2xtyq4cHU45zznTeBB6BWj7xil-n1htNWSUM4IZVRxsj1BOya1IFwa_hTtKNeMGNbwE3Rayg2lVCgun6MT0TDWMC526P4Q4vUEpIO4QMaHZR02nEasOf7illCnBd-H5Ts-wB1kwF2a-xBhwJfzvMY0wBh8pfz2AXdTiMG7Cbs44L3rU3ZLyhs-B7esGcrD_GpdfJqhvEDPRjcVePlYz9C3809fu89kf3Vx2X3cEy-0XMjAFKeD16bXCmozUlDjwFjb9kKNqufaiEZTZVrwYy9BGt8bZYQxtRWCiTP09ph7m9OPFcpi51A8TJOLkNZiuWyorHFaVPTNP-hNWnOsv6uUbqTULdOV4kfK51RKhtHe5jC7vFlG7S8t9qjFVi32QYvd6tHrx-i1n2H4c_LbQwXEESh1Fa8h_337P7E_AVN-mHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574557817</pqid></control><display><type>article</type><title>Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Bayram, Ozlem ; Haskologlu, Sule ; Bayrakoğlu, Deniz ; Bal, Sevgi Kostel ; Islamoglu, Candan ; Cipe, Funda Erol ; Kendirli, Tanil ; Kursun, Nazmiye ; Guner, Sukru Nail ; Yildiran, Alisan ; Bozdogan, Gunseli ; Yuksek, Mutlu ; Reisli, Ismail ; Dalva, Klara ; Aytekin, Caner ; Boztug, Kaan ; Dogu, Figen ; Ikinciogullari, Aydan</creator><creatorcontrib>Bayram, Ozlem ; Haskologlu, Sule ; Bayrakoğlu, Deniz ; Bal, Sevgi Kostel ; Islamoglu, Candan ; Cipe, Funda Erol ; Kendirli, Tanil ; Kursun, Nazmiye ; Guner, Sukru Nail ; Yildiran, Alisan ; Bozdogan, Gunseli ; Yuksek, Mutlu ; Reisli, Ismail ; Dalva, Klara ; Aytekin, Caner ; Boztug, Kaan ; Dogu, Figen ; Ikinciogullari, Aydan</creatorcontrib><description>Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life. Purpose and Methods This study reported retrospective data from 72 infants diagnosed with SCID including their major clinical features, HSCT characteristics, and outcomes over a 20-year period (1997–2017). Results Sixty-one of 72 SCID patients in the study underwent HSCT from 1997 to 2017. Median ages at the time of diagnosis and transplantation were 3.5 months and 5 months, respectively. Consanguinity was present in 68% of the patients, and T − B − NK + phenotype was predominantly identified. The overall survival was 80.3% over a 20-year period. However, the patients transplanted during an active infection had a lower survival rate of 73.9% compared to 100% for patients transplanted infection-free or with a previous infection that had resolved. The survival rate was significantly higher among recipients of HLA-identical transplants (92.9%), compared to recipients of mismatched related transplants (70%). The overall survival increased from 50 (1997–2006) to 85% (2007–2017) during the last 10 years. Conclusions This is one of the largest single-center studies in Turkey with extensive experience about SCID patients. Early diagnosis of SCID patients before the onset of an infection and early transplantation are shown to be extremely important factors affecting the outcome and increasing the survival regardless of the donor type based on the results of this study.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-021-01062-y</identifier><identifier>PMID: 34114123</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>B-Lymphocytes - immunology ; Biomedical and Life Sciences ; Biomedicine ; Consanguinity ; Diagnosis ; Early experience ; Female ; Hematopoietic Stem Cell Transplantation - adverse effects ; Histocompatibility antigen HLA ; Humans ; Immune system ; Immunology ; Infant ; Infections ; Infectious Diseases ; Internal Medicine ; Kaplan-Meier Estimate ; Killer Cells, Natural - immunology ; Lymphocytes B ; Male ; Medical Microbiology ; Original Article ; Patients ; Phenotypes ; Retrospective Studies ; Severe combined immunodeficiency ; Severe Combined Immunodeficiency - genetics ; Severe Combined Immunodeficiency - immunology ; Severe Combined Immunodeficiency - mortality ; Severe Combined Immunodeficiency - therapy ; Stem cell transplantation ; T-Lymphocytes - immunology ; Transplants &amp; implants ; Treatment Outcome ; Turkey - epidemiology</subject><ispartof>Journal of clinical immunology, 2021-10, Vol.41 (7), p.1563-1573</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d1620dc79b76ed16f0e6fd1188b36f6b2793470698ecfb5e59cb969399cfb3313</citedby><cites>FETCH-LOGICAL-c375t-d1620dc79b76ed16f0e6fd1188b36f6b2793470698ecfb5e59cb969399cfb3313</cites><orcidid>0000-0002-3298-5567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-021-01062-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-021-01062-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34114123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayram, Ozlem</creatorcontrib><creatorcontrib>Haskologlu, Sule</creatorcontrib><creatorcontrib>Bayrakoğlu, Deniz</creatorcontrib><creatorcontrib>Bal, Sevgi Kostel</creatorcontrib><creatorcontrib>Islamoglu, Candan</creatorcontrib><creatorcontrib>Cipe, Funda Erol</creatorcontrib><creatorcontrib>Kendirli, Tanil</creatorcontrib><creatorcontrib>Kursun, Nazmiye</creatorcontrib><creatorcontrib>Guner, Sukru Nail</creatorcontrib><creatorcontrib>Yildiran, Alisan</creatorcontrib><creatorcontrib>Bozdogan, Gunseli</creatorcontrib><creatorcontrib>Yuksek, Mutlu</creatorcontrib><creatorcontrib>Reisli, Ismail</creatorcontrib><creatorcontrib>Dalva, Klara</creatorcontrib><creatorcontrib>Aytekin, Caner</creatorcontrib><creatorcontrib>Boztug, Kaan</creatorcontrib><creatorcontrib>Dogu, Figen</creatorcontrib><creatorcontrib>Ikinciogullari, Aydan</creatorcontrib><title>Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><addtitle>J Clin Immunol</addtitle><description>Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life. Purpose and Methods This study reported retrospective data from 72 infants diagnosed with SCID including their major clinical features, HSCT characteristics, and outcomes over a 20-year period (1997–2017). Results Sixty-one of 72 SCID patients in the study underwent HSCT from 1997 to 2017. Median ages at the time of diagnosis and transplantation were 3.5 months and 5 months, respectively. Consanguinity was present in 68% of the patients, and T − B − NK + phenotype was predominantly identified. The overall survival was 80.3% over a 20-year period. However, the patients transplanted during an active infection had a lower survival rate of 73.9% compared to 100% for patients transplanted infection-free or with a previous infection that had resolved. The survival rate was significantly higher among recipients of HLA-identical transplants (92.9%), compared to recipients of mismatched related transplants (70%). The overall survival increased from 50 (1997–2006) to 85% (2007–2017) during the last 10 years. Conclusions This is one of the largest single-center studies in Turkey with extensive experience about SCID patients. Early diagnosis of SCID patients before the onset of an infection and early transplantation are shown to be extremely important factors affecting the outcome and increasing the survival regardless of the donor type based on the results of this study.</description><subject>B-Lymphocytes - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Consanguinity</subject><subject>Diagnosis</subject><subject>Early experience</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Infant</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocytes B</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Retrospective Studies</subject><subject>Severe combined immunodeficiency</subject><subject>Severe Combined Immunodeficiency - genetics</subject><subject>Severe Combined Immunodeficiency - immunology</subject><subject>Severe Combined Immunodeficiency - mortality</subject><subject>Severe Combined Immunodeficiency - therapy</subject><subject>Stem cell transplantation</subject><subject>T-Lymphocytes - immunology</subject><subject>Transplants &amp; implants</subject><subject>Treatment Outcome</subject><subject>Turkey - epidemiology</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1rFTEUhoMo9rb6B1xIwI2baD4mycSdDLYWLlS4ug6ZzJmaMpPUZKZl_r2xtyq4cHU45zznTeBB6BWj7xil-n1htNWSUM4IZVRxsj1BOya1IFwa_hTtKNeMGNbwE3Rayg2lVCgun6MT0TDWMC526P4Q4vUEpIO4QMaHZR02nEasOf7illCnBd-H5Ts-wB1kwF2a-xBhwJfzvMY0wBh8pfz2AXdTiMG7Cbs44L3rU3ZLyhs-B7esGcrD_GpdfJqhvEDPRjcVePlYz9C3809fu89kf3Vx2X3cEy-0XMjAFKeD16bXCmozUlDjwFjb9kKNqufaiEZTZVrwYy9BGt8bZYQxtRWCiTP09ph7m9OPFcpi51A8TJOLkNZiuWyorHFaVPTNP-hNWnOsv6uUbqTULdOV4kfK51RKhtHe5jC7vFlG7S8t9qjFVi32QYvd6tHrx-i1n2H4c_LbQwXEESh1Fa8h_337P7E_AVN-mHc</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Bayram, Ozlem</creator><creator>Haskologlu, Sule</creator><creator>Bayrakoğlu, Deniz</creator><creator>Bal, Sevgi Kostel</creator><creator>Islamoglu, Candan</creator><creator>Cipe, Funda Erol</creator><creator>Kendirli, Tanil</creator><creator>Kursun, Nazmiye</creator><creator>Guner, Sukru Nail</creator><creator>Yildiran, Alisan</creator><creator>Bozdogan, Gunseli</creator><creator>Yuksek, Mutlu</creator><creator>Reisli, Ismail</creator><creator>Dalva, Klara</creator><creator>Aytekin, Caner</creator><creator>Boztug, Kaan</creator><creator>Dogu, Figen</creator><creator>Ikinciogullari, Aydan</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3298-5567</orcidid></search><sort><creationdate>20211001</creationdate><title>Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes</title><author>Bayram, Ozlem ; Haskologlu, Sule ; Bayrakoğlu, Deniz ; Bal, Sevgi Kostel ; Islamoglu, Candan ; Cipe, Funda Erol ; Kendirli, Tanil ; Kursun, Nazmiye ; Guner, Sukru Nail ; Yildiran, Alisan ; Bozdogan, Gunseli ; Yuksek, Mutlu ; Reisli, Ismail ; Dalva, Klara ; Aytekin, Caner ; Boztug, Kaan ; Dogu, Figen ; Ikinciogullari, Aydan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d1620dc79b76ed16f0e6fd1188b36f6b2793470698ecfb5e59cb969399cfb3313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>B-Lymphocytes - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Consanguinity</topic><topic>Diagnosis</topic><topic>Early experience</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Infant</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocytes B</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Retrospective Studies</topic><topic>Severe combined immunodeficiency</topic><topic>Severe Combined Immunodeficiency - genetics</topic><topic>Severe Combined Immunodeficiency - immunology</topic><topic>Severe Combined Immunodeficiency - mortality</topic><topic>Severe Combined Immunodeficiency - therapy</topic><topic>Stem cell transplantation</topic><topic>T-Lymphocytes - immunology</topic><topic>Transplants &amp; implants</topic><topic>Treatment Outcome</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayram, Ozlem</creatorcontrib><creatorcontrib>Haskologlu, Sule</creatorcontrib><creatorcontrib>Bayrakoğlu, Deniz</creatorcontrib><creatorcontrib>Bal, Sevgi Kostel</creatorcontrib><creatorcontrib>Islamoglu, Candan</creatorcontrib><creatorcontrib>Cipe, Funda Erol</creatorcontrib><creatorcontrib>Kendirli, Tanil</creatorcontrib><creatorcontrib>Kursun, Nazmiye</creatorcontrib><creatorcontrib>Guner, Sukru Nail</creatorcontrib><creatorcontrib>Yildiran, Alisan</creatorcontrib><creatorcontrib>Bozdogan, Gunseli</creatorcontrib><creatorcontrib>Yuksek, Mutlu</creatorcontrib><creatorcontrib>Reisli, Ismail</creatorcontrib><creatorcontrib>Dalva, Klara</creatorcontrib><creatorcontrib>Aytekin, Caner</creatorcontrib><creatorcontrib>Boztug, Kaan</creatorcontrib><creatorcontrib>Dogu, Figen</creatorcontrib><creatorcontrib>Ikinciogullari, Aydan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayram, Ozlem</au><au>Haskologlu, Sule</au><au>Bayrakoğlu, Deniz</au><au>Bal, Sevgi Kostel</au><au>Islamoglu, Candan</au><au>Cipe, Funda Erol</au><au>Kendirli, Tanil</au><au>Kursun, Nazmiye</au><au>Guner, Sukru Nail</au><au>Yildiran, Alisan</au><au>Bozdogan, Gunseli</au><au>Yuksek, Mutlu</au><au>Reisli, Ismail</au><au>Dalva, Klara</au><au>Aytekin, Caner</au><au>Boztug, Kaan</au><au>Dogu, Figen</au><au>Ikinciogullari, Aydan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><addtitle>J Clin Immunol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>41</volume><issue>7</issue><spage>1563</spage><epage>1573</epage><pages>1563-1573</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><abstract>Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life. Purpose and Methods This study reported retrospective data from 72 infants diagnosed with SCID including their major clinical features, HSCT characteristics, and outcomes over a 20-year period (1997–2017). Results Sixty-one of 72 SCID patients in the study underwent HSCT from 1997 to 2017. Median ages at the time of diagnosis and transplantation were 3.5 months and 5 months, respectively. Consanguinity was present in 68% of the patients, and T − B − NK + phenotype was predominantly identified. The overall survival was 80.3% over a 20-year period. However, the patients transplanted during an active infection had a lower survival rate of 73.9% compared to 100% for patients transplanted infection-free or with a previous infection that had resolved. The survival rate was significantly higher among recipients of HLA-identical transplants (92.9%), compared to recipients of mismatched related transplants (70%). The overall survival increased from 50 (1997–2006) to 85% (2007–2017) during the last 10 years. Conclusions This is one of the largest single-center studies in Turkey with extensive experience about SCID patients. Early diagnosis of SCID patients before the onset of an infection and early transplantation are shown to be extremely important factors affecting the outcome and increasing the survival regardless of the donor type based on the results of this study.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34114123</pmid><doi>10.1007/s10875-021-01062-y</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3298-5567</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0271-9142
ispartof Journal of clinical immunology, 2021-10, Vol.41 (7), p.1563-1573
issn 0271-9142
1573-2592
language eng
recordid cdi_proquest_miscellaneous_2540518873
source MEDLINE; SpringerLink Journals
subjects B-Lymphocytes - immunology
Biomedical and Life Sciences
Biomedicine
Consanguinity
Diagnosis
Early experience
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Histocompatibility antigen HLA
Humans
Immune system
Immunology
Infant
Infections
Infectious Diseases
Internal Medicine
Kaplan-Meier Estimate
Killer Cells, Natural - immunology
Lymphocytes B
Male
Medical Microbiology
Original Article
Patients
Phenotypes
Retrospective Studies
Severe combined immunodeficiency
Severe Combined Immunodeficiency - genetics
Severe Combined Immunodeficiency - immunology
Severe Combined Immunodeficiency - mortality
Severe Combined Immunodeficiency - therapy
Stem cell transplantation
T-Lymphocytes - immunology
Transplants & implants
Treatment Outcome
Turkey - epidemiology
title Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A38%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single-Center%20Study%20of%2072%20Patients%20with%20Severe%20Combined%20Immunodeficiency:%20Clinical%20and%20Laboratory%20Features%20and%20Outcomes&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Bayram,%20Ozlem&rft.date=2021-10-01&rft.volume=41&rft.issue=7&rft.spage=1563&rft.epage=1573&rft.pages=1563-1573&rft.issn=0271-9142&rft.eissn=1573-2592&rft_id=info:doi/10.1007/s10875-021-01062-y&rft_dat=%3Cproquest_cross%3E2574557817%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2574557817&rft_id=info:pmid/34114123&rfr_iscdi=true